X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (319) 319
Publication (53) 53
Conference Proceeding (31) 31
Patent (12) 12
Magazine Article (2) 2
Book / eBook (1) 1
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (107) 107
female (82) 82
male (80) 80
index medicus (74) 74
middle aged (69) 69
oncology (68) 68
aged (53) 53
adult (48) 48
hematology (40) 40
mathematics (38) 38
adolescent (37) 37
melanoma (37) 37
treatment outcome (36) 36
disease-free survival (34) 34
cancer (32) 32
melanoma - drug therapy (27) 27
prognosis (27) 27
neoplasm staging (24) 24
skin neoplasms - drug therapy (24) 24
survival (24) 24
aged, 80 and over (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
melanoma - pathology (21) 21
therapy (21) 21
survival analysis (20) 20
clinical trials (19) 19
mathematics - algebraic topology (18) 18
skin neoplasms - pathology (18) 18
analysis (17) 17
child (17) 17
melanoma - mortality (17) 17
acute myelogenous leukemia (16) 16
antineoplastic agents - therapeutic use (16) 16
chemotherapy (16) 16
hematology, oncology and palliative medicine (16) 16
risk (16) 16
child, preschool (15) 15
cutaneous melanoma (15) 15
infant (15) 15
mathematics - group theory (15) 15
remission induction (15) 15
risk factors (15) 15
skin neoplasms - mortality (15) 15
medicine, general & internal (14) 14
melanoma - surgery (14) 14
proportional hazards models (14) 14
research (14) 14
young adult (14) 14
chemotherapy, adjuvant (13) 13
follow-up studies (13) 13
interferon-alpha - therapeutic use (13) 13
malignant-melanoma (13) 13
mathematics - algebraic geometry (13) 13
cohomology (12) 12
drug administration schedule (12) 12
high-risk melanoma (12) 12
survival rate (12) 12
time factors (12) 12
abridged index medicus (11) 11
acute myeloid-leukemia (11) 11
care and treatment (11) 11
interferon (11) 11
kaplan-meier estimate (11) 11
leukemia (11) 11
nanoparticles (11) 11
skin neoplasms - surgery (11) 11
trial (11) 11
acute myeloid leukemia (10) 10
childhood (10) 10
children (10) 10
lower central series (10) 10
melanoma - secondary (10) 10
myelodysplastic syndromes - mortality (10) 10
oncology, experimental (10) 10
pegylated interferon-alpha-2b (10) 10
precursor cell lymphoblastic leukemia-lymphoma - mortality (10) 10
prognostic-factors (10) 10
bone-marrow-transplantation (9) 9
combined modality therapy (9) 9
homology (9) 9
leukemia, myeloid, acute - mortality (9) 9
medicine & public health (9) 9
multicenter (9) 9
adjuvant therapy (8) 8
age factors (8) 8
algebra (8) 8
algebraic topology (8) 8
antibodies, monoclonal - therapeutic use (8) 8
antineoplastic agents - administration & dosage (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
article (8) 8
drug therapy (8) 8
europe (8) 8
expression (8) 8
geometry (8) 8
health aspects (8) 8
homotopy theory (8) 8
intensive chemotherapy (8) 8
ipilimumab (8) 8
leukemia, myeloid, acute - drug therapy (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 522 - 530
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1845 - 1855
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 THERAPY | EORTC 18952 | TUMOR BURDEN | CUTANEOUS MELANOMA | PHASE-3 TRIAL | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | Risk groups | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2013, Volume 31, Issue 19, pp. 2388 - 2395
Journal Article
Journal Article
Journal Article
Proceedings of the London Mathematical Society, ISSN 0024-6115, 06/2017, Volume 114, Issue 6, pp. 961 - 1004
Journal Article
Journal Article
International Mathematics Research Notices, ISSN 1073-7928, 01/2018
Given a compact, connected Lie group $K$, we use principal $K$-bundles to construct manifolds with prescribed finite-dimensional algebraic models. Conversely,... 
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 01/2017, Volume 376, Issue 4, p. 399
Journal Article